Metraipolis › archive › dc_7f7683bc318c
Cardiometabolic 2.0: Redefining Cardiovascular Prevention Through SGLT-2 Inhibitors and GLP-1 Receptor Agonists — Europe PMC PMID:42195313
- Source
- Europe PMC (en)
- Original
- https://europepmc.org/article/MED/42195313
- DOI
- 10.3390/life16050756
- License (as archived)
- solo-consultazione
- Archived
- 2026-11-02T22:02:38.709Z
- SHA-256 of the archived text
0f515c3f9da9cfaac9d0e4908ff233684c6f49a7322070392fe20598062d4704- Stable URL of this page
https://metraipolis.com/documento/dc_7f7683bc318c
How to cite
Cardiometabolic 2.0: Redefining Cardiovascular Prevention Through SGLT-2 Inhibitors and GLP-1 Receptor Agonists — Europe PMC PMID:42195313 — Europe PMC (en), https://europepmc.org/article/MED/42195313 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_7f7683bc318c (Metraipolis archive dc_7f7683bc318c, sha256 0f515c3f9da9cfaac9d0e4908ff233684c6f49a7322070392fe20598062d4704)
BibTeX
@misc{dc7f7683bc318c,
title = {Cardiometabolic 2.0: Redefining Cardiovascular Prevention Through SGLT-2 Inhibitors and GLP-1 Receptor Agonists — Europe PMC PMID:42195313},
howpublished = {Europe PMC (en)},
url = {https://europepmc.org/article/MED/42195313},
note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_7f7683bc318c; sha256 0f515c3f9da9cfaac9d0e4908ff233684c6f49a7322070392fe20598062d4704},
year = {2026}
}Archived text
The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42195313. Agents can read the archived copy with the MCP tool read_document.